您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8473 处方药 8099 非处方药 268 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 作用于消化系统药物->治疗肠道疾病
处方药:处方药
包装规格: 4克/60毫升/瓶 28瓶/箱
计价单位:
  点击放大  
生产厂家中文参考译名:
MEDA PHARMS
生产厂家英文名:
MEDA PHARMS
该药品相关信息网址1:
www.rxlist.com/rowasa-drug.htm
该药品相关信息网址2:
www.drugs.com/cdi/rowasa-enema.html
该药品相关信息网址3:
http://www.medicinenet.com/mesalamine/article.htm
原产地英文商品名:
ROWASA ENEMA KIT 4G/60ML/BOTTLE 28BOTTLES/CASE
原产地英文药品名:
MESALAMINE WITH CLEANSING WIPES
原产地英文化合物名称:
5-Amino Salicylic Acid
中文参考商品译名:
ROWASA灌肠剂套装 4克/60毫升/瓶 28瓶/箱
中文参考药品译名:
美沙拉嗪和清洁湿巾
中文参考化合物名称:
5-氨基水杨酸
原产地国家批准上市年份:
1987/12/24
英文适应病症1:
Ulcerative Colitis
英文适应病症2:
Ulcerative proctitis
英文适应病症3:
Crohn's Disease
临床试验期:
完成
中文适应病症参考翻译1:
溃疡性结肠炎
中文适应病症参考翻译2:
溃疡性直肠炎
中文适应病症参考翻译3:
克隆氏病
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201271200342423.PDF,201271200341418.PDF)的“原文Priscribing Information”为准
---------------------------------------------------------------
 部分中文Rowasa处方资料(仅供参考)

英文药名: Rowasa Enema(Mesalamine/5-ASA)

中文药名: 美沙拉嗪&5 -氨基水杨酸灌肠剂

药品名称
通用名称: 美沙拉嗪,5-氨基水杨酸
英文名: Mesalazine,5-Amino Salicylic Acid, Asacolitin, Claversal, Enterasin, Etiasa, Fisalamine, FIV-ASA Mesalazinum, Mesasal, Zinc 5-aminosalicylate, Pentasa-R, Rowasa, Salofalk, Saloflk

药理作用
对肠壁的炎症有显著的抑制作用;美沙拉嗪可以抑制引起炎症的前列腺素的合成和炎性介质白三烯的形成,从而对肠粘膜的炎症起显著抑制作用。对有炎症的肠壁的结缔组织效果更佳。

适应症
用于溃疡性结肠炎、溃疡性直肠炎和克隆氏病(Crohn's Disease)。

不良反应 
可能出现轻度的胃部不适。

注意事项 
①对水杨酸类药物以及本品的赋形剂过敏者忌用。
②肝肾功能不全者慎用;妊娠及哺乳期妇女慎用;两岁以下儿童不宜用。
③与氰钴胺片(VitB12片)同有,将影响氰钴胺片的吸收。
④服药时要整粒囫囵吞服,绝不可嚼碎或压碎。

GENERIC NAME: mesalamine (5-aminosalicylic acid)

BRAND NAMES: Pentasa, Rowasa, Asacol, Lialda, Canasa

DRUG CLASS AND MECHANISM: Mesalamine is a drug used for treating ulcerative colitis. The exact mechanism of mesalamine is not known but is believed to be by reducing inflammation in the colon. Ulcerative colitis and other inflammatory diseases cause excessive production of chemicals, for example, prostaglandins, that produce inflammation in the colon. Prostaglandins are produced by the enzymes, cyclooxygenase and lipoxygenase. These enzymes are over-active in individuals with ulcerative colitis. Mesalamine may work by blocking the activity of cyclooxygenase and lipoxygenase, thereby, reducing the production of prostaglandins. Reduced production of prostaglandins decreases inflammation in the colon and the symptoms associated with ulcerative colitis. Available forms of mesalamine differ in their route of administration and how often they are administered. Mesalamine was approved by the FDA in December 1987.

PRESCRIPTION: Yes

GENERIC AVAILABLE: Yes (rectal enema)

PREPARATIONS:
Tablets (delayed release): 400 mg (Asacol), 1.5 g (Lialda).
Capsules (extended or delayed release): 375 mg (Apriso); 250, 500 mg (Pentasa).
Rectal enema (Rowasa): 4 g per 60 mL.
Rectal suppositories (Canasa): 1000 mg.

STORAGE: The tablets, capsules, and enemas should be stored at room temperature, 15-30 C (59-86 F). The suppositories should be stored below 25 C (77 F) without freezing.

PRESCRIBED FOR: Mesalamine is used for the treatment of mild to moderately severe ulcerative colitis. The suppositories are limited to use in ulcerative colitis involving only the rectum (proctitis) and the enemas to colitis involving only the part of the colon close to the rectum (distal colitis) or proctitis. While the benefits of mesalamine can be seen within 3 to 21 days of starting therapy, it may take up to three to six weeks for the enemas and suppositories, six weeks for the tablets, and eight weeks for the capsules to have maximum effect.

DOSING:
Lialda: 2.4-4.8 g once daily with food
Apriso: 1.5 g orally once daily
Pentasa: 1 g four times daily
Asacol: 800 mg two or three times daily
Rowasa: One rectal application (4 g per 60 mL) once a day, preferably at bedtime, and retained for approximately 8 hours.
Canasa: One suppository (1,000 mg) daily at bedtime. The suppository should be retained in the rectum for one to three hours or more if possible to achieve maximum benefit.

DRUG INTERACTIONS: Oral mesalamine formulations are associated with several drug interactions. Combining mesalamine with drugs that affect kidney function, for example, nonsteroidal antiinflammatory drugs (NSAIDs) or ibuprofen may increase the likelihood of reduced function of the kidneys. Concurrent use of mesalamine and 6-mercaptopurine or azathioprine (Imuran) may increase the likelihood of disorders of the blood cells, particularly reduced numbers of cells. Mesalamine may increase the blood thinning effect of warfarin (Warfarin).

PREGNANCY: There are no adequate human studies of mesalamine during pregnancy. Mesalamine is known to cross the placenta into the fetus, but animal studies revealed no evidence of harm to the fetus. Mesalamine should only be used during pregnancy if it is felt that the benefit of its use justifies the unknown risks.

NURSING MOTHERS: Mesalamine is excreted in breast milk. Mesalamine should only be used by nursing mothers if it is felt that the benefit of its use justifies the potential but unknown risk to the infant.

SIDE EFFECTS: The most common side effects of mesalamine are headache and flatulence. Hair loss and itching also may occur. Infrequent side effects include increased heart rate, acne, pancreatitis, back pain, fatigue, tremor, ear pain, and blood disorders.

Kidney dysfunction has been associated with mesalamine. Kidney function should be evaluated prior to and periodically during mesalamine therapy.

Mesalamine may cause an acute intolerance syndrome that resembles a flare of inflammatory bowel disease (Crohn's disease or ulcerative colitis) with cramping, abdominal pain, and bloody diarrhea. Fever, headache, itching, and rash also may occur. Symptoms usually subside once mesalamine is discontinued.

Mesalamine enemas contain sulfites and should be avoided in persons who are sensitive to sulfites.

Since mesalamine is related to aspirin in structure, individuals who are allergic to aspirin should not take mesalamine.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201271200342423.PDF,201271200341418.PDF)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2012-7-12
附件:




201271200342423.PDF    

201271200341418.PDF    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com